Serum Institute of India to acquire 20 percent stake in IntegriMedical
Serum Institute of India (SII) on Friday announced a strategic investment in IntegriMedical, acquiring a 20 percent stake in the company, to advance Needle-Free Injection System technology.
According to the company’s statement, the partnership
between SII and IntegriMedical aligns with SII’s vision of ‘Health for All’ and
IntegriMedical’s mission to ‘Transform Healthcare Globally’ by providing
patient comfort, ensuring increased patient compliance, reducing needle-stick
injuries, and enhancing the efficacy of liquid medication via needle-free
dispersion.
IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS)
that utilizes high-velocity jet stream using mechanical power to effectively
and consistently administer biologics and drugs. The innovative drug delivery
solution aims to alleviate pain during administration, providing needle-phobic
patients with a pleasant and stress-free experience, the company claimed.
Comments
Post a Comment